An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) announced its participation in the LifeSci Partners 11th Annual Corporate Access Event, taking place virtually from January 5-7, 2022. The management team will engage in one-on-one meetings with investors during the event to discuss company developments. DiaMedica focuses on developing novel treatments for neurological disorders and kidney diseases, with lead candidate DM199 showing promising early clinical results. The company is advancing its pivotal ReMEDy Phase 2/3 trial for acute ischemic stroke and completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.
Positive
Participation in a key investor event enhances visibility and investor engagement.
Ongoing clinical trials for DM199 show promise in treating acute ischemic stroke and chronic kidney disease.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually from January 5-7, 2022.
The DiaMedica management team will be available for one-on-one meetings with interested investors during the event. Register here to submit a meeting request.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Its lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, DiaMedica has initiated and commenced enrollment in its pivotal ReMEDy Phase 2/3 trial in the treatment of AIS and is completing enrollment in its REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.
For Investor Inquiries:
Tim McCarthy Managing Director, LifeSci Advisors, LLC tim@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
What is the significance of DiaMedica's participation in the LifeSci Partners event?
DiaMedica's participation allows for increased visibility among investors and the opportunity to discuss ongoing trials and company developments.
What are the key clinical trials that DiaMedica is currently conducting?
DiaMedica is conducting the ReMEDy Phase 2/3 trial for acute ischemic stroke and is completing enrollment in the REDUX Phase 2 trial for chronic kidney disease.
When is the LifeSci Partners 11th Annual Corporate Access Event?
The event is scheduled to take place virtually from January 5-7, 2022.
What is DM199 and its relevance to DiaMedica's strategy?
DM199 is DiaMedica's lead candidate, a synthetic form of the KLK1 protein aimed at treating acute ischemic stroke and chronic kidney disease.
